Drug intelligence / Profile preview

TDENV-LAV

Development stage: Phase 1
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**TDENV-LAV** is an investigational tetravalent live-attenuated dengue vaccine, also designated formulation 17, designed to induce protective immunity against dengue virus serotypes 1, 2, 3, and 4. Developed from the Walter Reed Army Institute of Research live-attenuated dengue vaccine program with GSK involvement, it was evaluated subcutaneously in healthy adults as part of heterologous prime-boost regimens with tetravalent dengue purified inactivated vaccine. In the completed Phase 1 study NCT02239614, regimens in which the inactivated vaccine primed and TDENV-LAV boosted generated high neutralizing-antibody responses and tetravalent seroconversion.

Other names: tetravalent dengue live attenuated virus vaccine formulation 17tetravalent live-attenuated dengue virus vaccine

Beyond the preview

Go deeper on TDENV-LAV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TDENV-LAV.

Explore the full profile